The results of the pediatric vaccination with the Soberana 02 and Soberana Plus immunogen scheme were presented this Wednesday to Italy's regulatory authority.

The Cuban delegation led by the president of the Finlay Institute of Vaccines, Dr. Vicente Vérez, is made up of experts from this institution and from the Group of the Biotechnological and Pharmaceutical Industries of Cuba (BioCubaFarma), reports Cubadebate.

The findings of the clinical trials were presented to Giorgio Palù, president of the Italian Drug Agency (AIFA), and to Nicola Magrini, general director of the regulatory body.

The Agency for Cultural and Economic Exchange with Cuba (Aicec, for its Italian acronym), in a tweet replicated by IFV, highlights: The "scientific results shared with the international scientific community and under the endorsement of immunization to 1.7 million Cuban children."

Likewise, the Aicec reported on the presentation of Sovereign 02 in the Italian Chamber of Deputies, together with legislators Erasmo Palazzotto and Gilda Sportiello, the latter from the Social Affairs Commission.

Cubadebate reports that the Italian institution acknowledged in a tweet the proven safety of Soberana 02 in children aged two and older. In this regard, it stressed: "The importance of the Cuban pediatric vaccine cannot be ignored, given its scientific evidence.

The Cuban scientists, including Dr. Dagmar García, IFV Research Director, also met with the General Director of Prevention of the Italian Ministry of Health, Giovanni Rezza.

On March 3, the Finlay Vaccine Institute delegation arrived in Italy on a working visit and its program of activities there will conclude on March 12.

In November 2021, a clinical trial Soberana Plus Turin began, whose purpose was to evaluate the immunogen in Covid-19 convalescents and subjects with no history of the disease, but immunized with other vaccines, according to the official website of the Ministry of Science, Technology and Environment (CITMA).

The clinical study was carried out at the La Pradera International Health Center in the Cuban capital, while in Italy the "Amadeo di Savoia" Hospital in the city of Turin was selected.